Physician profile
Setu K Vora
NPI 1437146776
$19,158.65
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,777 · 2021: $2,768 · 2022: $2,914 · 2023: $3,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,566.47 | 2019 | |
| Pfizer INC. | $3,700.00 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,820.00 | 2022 | |
| Amgen INC. | $2,748.00 | 2021 | |
| Glaxosmithkline, LLC. | $176.98 | 2019 | |
| Biomerieux INC | $93.59 | 2022 | |
| Sunovion Pharmaceuticals INC. | $33.20 | 2019 | |
| Advanced Respiratory, INC | $20.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Setu Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.